SupplySide Global 2026: Clasado Biosciences and Probi unpack the next phase of gut health

Clasado Biosciences and Probi will feature their biotics at the upcoming SupplySide Global trade show (Oct 28–30), as consumer demand for gut health expands to more targeted solutions. The companies tell Nutrition Insight about trends shaping the biotics market. 

At the event in Las Vegas, Nevada, US, Clasado Biosciences will showcase its flagship prebiotic galactooligosaccharide (GOS) ingredient, Bimuno GOS, while Probi will highlight its pro- and postbiotics, such as the Lactiplantibacillus plantarum LP299V strain. 

Marcelo Durante, VP of sales and marketing at Clasado Biosciences, says that gut health has been used as a “broad halo” description for many years, where consumers knew the term but did not understand the mechanics or the gut microbiome’s influence on health and well-being.

“That is changing quickly,” he notes. “Consumers are increasingly understanding that the gut microbiome is linked to much more than just digestion.” 

He highlights that consumers increasingly understand how gut health can support immune resilience or help with stress and sleep, not only with easing occasional gut discomfort or gas. 

Durante says this change has two key effects. “First, consumers are reading labels more closely. They want to see specific ingredients with a clear benefit at a research-proven dose, which can easily be fact-checked based on the tools available.”

Second, he notes that prebiotics are moving from a supporting role to the center stage. Brands and their formulators are recognizing that feeding the beneficial bacteria already in the gut is a strong, evidence-based strategy in its own right.

Consumers are increasingly understanding that the gut microbiome is linked to much more than just digestion, says Durante.“The result of these changes is a market that rewards precision,” underscores Durante. “Consumers are more engaged than ever before, asking what an ingredient does, how much of it is in the product, and what evidence supports it.”

Evidence-based solutions

Bryan Gray, senior marketing manager, North America at Probi, observes that consumers seek evidence-based solutions that connect gut health with broader areas of well-being, from immune and metabolic health to sports and active nutrition.

“Consumer expectations are moving beyond digestion as concepts such as the gut-brain connection embed themselves into the mainstream.”

“We see particularly strong momentum around metabolic wellness, women’s health, and healthy aging, as consumers increasingly look for solutions that support multiple aspects of health. The microbiome is an effective and accessible lever for improving health span and the key factors that play into it.”

At SupplySide Global 2026, Probi will showcase its expanding biotic portfolio, says Gray. The company will highlight its Rham271h postbiotic and present new clinical data for LP299V and LpGOS42.

“Together, they demonstrate how targeted science, formulation flexibility, and new biotic formats can help brands respond to evolving consumer needs.”

In September 2026, a review highlighted that Probi’s LP299V probiotic strain increases fractional non-heme iron absorption by 20–50% by enhancing solubility and reducing dietary inhibitors.

Probi sees particularly strong momentum around metabolic wellness, women’s health, and healthy aging.The company also gained validation in Japan for its first clinical study in the country on LP299V. The trial showed that consuming the strain daily improved bowel habits in healthy adults who are prone to loose stools.

Formulation challenges

The nutrition industry increasingly offers ingredients in new delivery formats to target pill fatigue. For example, Sabinsa will bring effervescent tablets, powder mixes, and stick packs to SupplySide Global 2026.

Durante notes that brands need to address several formulation challenges when incorporating prebiotic ingredients in formats beyond capsules, such as beverages, functional foods, gummies, and powders.

“The first challenge is dose,” he notes. “Many prebiotic fibers need 5 g or more daily to deliver a proven benefit, which can be challenging to fit into a gummy or capsule. Efficacy at a low dose, which we’ve demonstrated with Bimuno GOS, changes what’s possible.”

Stability is the second challenge, he adds. Prebiotics are typically very stable and can be exposed to heat, low pH, and moisture, and have a long shelf life.

However, he notes that applications that feature a high water content can cause instability to occur sooner than expected, and the benefit on the label may not match what’s in the pack. Durante says that Bimuno GOS is stable across typical processing conditions, which gives formulators flexibility.

The third challenge is tolerability, he continues. “Some prebiotics cause bloating or discomfort at higher doses, which is the opposite of what a gut health consumer wants. Selective, low-dose ingredients help avoid that.”

“Finally, there’s the sensory impact. Taste, texture, and sweetness all matter in everyday foods and gummies. An ingredient that behaves predictably, with a clean, mildly sweet profile, makes life easier for product developers.”

Capsule-compatible biotics

Durante points to a Metabolites study that Clasado Biosciences conducted with Cryptobiotix, showing that Bimuno GOS exerted a prebiotic effect at a “capsule-compatible” dose of 380 mg of active GOS per day.

The study authors concluded that the ingredient offers greater flexibility in nutritional product formulation and consumer convenience. “The strong response at the lowest dose suggests effective microbiome modulation at lower levels than previously expected.”

Durante says consumers are reading labels more closely and want to see specific ingredients, with a clear, evidence-backed benefit.Bimuno GOS can be added to a range of formats, adds Durante. “Examples include daily gut health supplements, low-dose capsules, powders, and gummies.”

Probi’s Gray adds that postbiotics also open new formulation opportunities. These remain effective without the need for live bacteria, unlike probiotics.

“Rham271h offers enhanced pH and heat resistance and improved shelf stability, helping overcome some of the challenges associated with live probiotics while creating opportunities across supplements, functional foods, and beverages,” says Gray.

Advancing microbiome science

The role of microbiome science is expanding across different health categories, note the experts. Durante says that the gut microbiome acts as a central hub connecting gut health with the immune system, the brain, and, increasingly, physical performance and longevity.

“Our approach is to follow the mechanism, develop strong scientific understanding, and make it more accessible for brands and their customers.”

He explains that Bimuno GOS is built to selectively nourish beneficial bacteria such as bifidobacteria, which produce short-chain fatty acids and help maintain the gut barrier. He says that those effects work upstream of many varied outcomes.

“To build on that, we’ve nurtured a long-term research program that looks at prebiotic effects, digestive health, immune function, and brain health across a wide variety of cohorts.”

“For example, most recently in a sports nutrition-based study, six weeks of Bimuno GOS reduced a marker of gut barrier damage and shortened the average duration of upper respiratory symptoms.”

Durante says this study is a good example of how one ingredient can be relevant to very different categories, provided each application is backed by its own validated evidence.

Gray notes that postbiotics open up new formulation opportunities as these remain effective without the need for live bacteria, unlike probiotics.He underscores the importance of clinical trials as these bridge the gap between a change in the microbiome and a benefit that a person can actually notice.

“Showing that an ingredient increases bifidobacteria is valuable, but showing that it reduces digestive discomfort, supports immune resilience, or improves well-being in a randomized, placebo-controlled trial is what helps to establish and strengthen consumer trust.”

What’s next?

For new microbiome products to succeed in an increasingly crowded market, Durante says ingredient science “comes first.” He underscores that a product must deliver the benefits based on evidence, not just refer to it.

“That means the same ingredient, at the dose studied, for the benefit claimed,” he details. “As consumers become more informed, they’ll naturally become more critical of claims that cannot be backed up.”

“Format is the next significant differentiator,” he continues. “The best science in the world won’t help if people don’t take the product consistently. Convenient formats that fit into daily routines, such as a drink, a gummy, or a scoop in a morning coffee, support the regular use that microbiome benefits depend on.”

Probi’s Gray says the market will increasingly focus on targeted, science-backed solutions that fit specific consumer needs.

“I expect the next phase of growth to come from a broader biotic platform that combines probiotics with prebiotics, synbiotics, and postbiotics, alongside new delivery formats and applications beyond traditional gut health,” he concludes.